关于公司 2026 年限制性股票激励计划相关事项的核查意见 西藏易明西雅医药科技股份有限公司（以下简称"公司"）第四届董事会薪 酬与考核委员会根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中 华人民共和国证券法》（以下简称"《证券法》"）、《上市公司股权激励管理办法》 （以下简称"《管理办法》"）等法律、法规和规范性文件以及《公司章程》的有 关规定，对《公司 2026 年限制性股票激励计划（草案）》（以下简称"本次激励 计划"）及其他相关资料进行了核查，发表核查意见如下： 1、公司不存在《管理办法》等有关法律、法规和规范性文件规定的不得实 施股权激励计划的下列情形，公司具备实施股权激励计划的主体资格： 西藏易明西雅医药科技股份有限公司 董事会薪酬与考核委员会 （1）最近一个会计年度财务会计报告被注册会计师出具否定意见或者无法 表示意见的审计报告； （2）最近一个会计年度财务报告内部控制被注册会计师出具否定意见或无 法表示意见的审计报告； （5）法律法规规定不得参与上市公司股权激励的； （6）中国证监会认定的其他情形。 （3）上市后最近 36 个月内出现过未按法律法规、《公司章程》、公开承诺进 行利 ...

证券代码：002826 证券简称：易明医药 公告编号：2026-002 西藏易明西雅医药科技股份有限公司 第四届董事会第三次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 西藏易明西雅医药科技股份有限公司（以下简称"公司"）第四届董事会第 三次会议已于 2026 年 2 月 10 日在公司会议室以现场与通讯相结合方式召开。本 次会议于 2026 年 2 月 7 日以电子邮件方式通知了全体董事。 本次会议应到董事 7 人，实到董事 7 人。公司高级管理人员列席了本次会议。 会议由董事长付丽华女士召集和主持，董事会秘书李前进女士出席并记录了本次 会议。本次会议的召集、召开和表决程序符合《中华人民共和国公司法》（以下 简称"《公司法》"）等相关法律法规以及《西藏易明西雅医药科技股份有限公 司章程》（以下简称"《公司章程》"）的规定。 二、董事会会议审议情况 （一）审议通过了《关于公司<2026 年限制性股票激励计划（草案）>及其 摘要的议案》； 为进一步完善公司法人治理结构，建立、健全公司长效激励约束机制，吸引 和留住董事、高级 ...

Group 1 - The core point of the article is that Yiming Pharmaceutical (002826.SZ) has stated on its investor interaction platform that the company does not have any original research drug products [1]

Group 1 - The core point of the article is that Yiming Pharmaceutical (002826.SZ) has stated on its investor interaction platform that the company does not have any original research drug products [1]

Group 1 - The core point of the article is that Yiming Pharmaceutical (002826) reported a total of 17,675 shareholders as of January 30, 2026 [1]

Market Performance - The chemical pharmaceutical sector increased by 1.41% on February 3, with Yiming Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 4067.74, up 1.29%, while the Shenzhen Component Index closed at 14127.1, up 2.19% [1] Top Gainers in Chemical Pharmaceutical Sector - Yiming Pharmaceutical (002826) closed at 20.98, up 9.27% with a trading volume of 269,200 shares and a transaction value of 559 million [1] - Yuandong Biological (688513) closed at 68.90, up 8.85% with a trading volume of 64,600 shares [1] - Nami Technology (688690) closed at 29.00, up 7.01% with a trading volume of 93,900 shares and a transaction value of 265 million [1] - Lianhuan Pharmaceutical (600513) closed at 20.15, up 5.94% with a trading volume of 162,200 shares and a transaction value of 323 million [1] Top Losers in Chemical Pharmaceutical Sector - Shuangbi Pharmaceutical (002038) closed at 6.41, down 7.10% with a trading volume of 801,300 shares and a transaction value of 511 million [2] - Haizhi Pharmaceutical (002653) closed at 47.50, down 5.47% with a trading volume of 90,200 shares and a transaction value of 430 million [2] - Nuo Cheng Jianhua (688428) closed at 21.13, down 3.78% with a trading volume of 163,500 shares [2] Capital Flow Analysis - The chemical pharmaceutical sector experienced a net outflow of 42.01 million from institutional investors, while retail investors saw a net inflow of 651 million [2] - The main capital inflow was observed in Yiming Pharmaceutical with 58.98 million, while it faced a net outflow of 58.77 million from retail investors [3] - Other notable inflows included Guangsheng Tang (300436) with 14.8 million from main capital, while it faced a net outflow of 95.56 million from retail investors [3]

Policy Developments - The National Healthcare Security Administration and the National Administration of Traditional Chinese Medicine announced the inclusion of Beijing and other regions in a pilot program for disease-based payment for traditional Chinese medicine [2] Drug and Device Approvals - Heng Rui Medicine received acceptance for a new indication application for its innovative drug, injection of Carrelizumab combined with Apatinib, for the treatment of unresectable hepatocellular carcinoma [4] - Lifesun Pharmaceutical announced that its Aminophylline tablets passed the consistency evaluation for generic drugs, which is expected to enhance market competitiveness [5] - Eli Lilly's Metabolically Associated Fatty Liver Disease indication for Tirzepatide has been included in the list of breakthrough therapies by the National Medical Products Administration [6] Financial Reports - Yiming Pharmaceutical projected a net profit increase of 61.12% to 122.08% for 2025, driven by the growth of its core product, Miglitol tablets [8] - Innovation Medical forecasted a net loss of 26 million to 33 million yuan for 2025, primarily due to tax expenses and adjustments in healthcare policies [9] Capital Markets - Kangchen Pharmaceutical upgraded its share repurchase plan to a total of 300 million Hong Kong dollars, extending the buyback period until the next annual general meeting [11] Industry Developments - Huawei Cloud is set to launch a smart healthcare section as part of its AI "Dream Factory" initiative, aiming to integrate top medical resources and advanced technology [14] - AstraZeneca announced plans to invest 15 billion USD in China by 2030 to expand research and production capabilities [16]

Group 1 - The company expects a positive net profit for the year 2025, with an increase of over 50% compared to the previous year [1] - The performance forecast period is from January 1, 2025, to December 31, 2025 [1] - The preliminary estimate of non-recurring gains and losses is expected to impact net profit by approximately 43 million yuan, primarily from government subsidies and compensation from Bositai [1] Group 2 - The company has focused on developing its self-produced products, particularly the core product Miglitol tablets, which has led to increased sales and overall profit growth [1] - There are no significant disagreements between the company and the auditing accounting firm regarding the performance forecast [1]

Group 1: Company Announcements - Meinian Health plans to participate in the restructuring of Zhejiang Bangjie Holdings, aiming to become the controlling shareholder post-restructuring [1] - Silver Industry's gold and silver product revenues are low, with gold sales contributing 18.67% and silver 4.54% to total revenue in H1 2025 [2] - Tianneng Wind Power has decided to implement long-term production halts for six wholly-owned subsidiaries to optimize resource allocation and focus on core offshore wind power business [3] Group 2: Price and Supply Risks - Tongling Nonferrous Metals reports significant uncertainty in the prices of cathode copper and other main products, with low self-sufficiency in copper concentrate posing supply stability risks [4] - ST Aowei received a notice of termination of listing due to market capitalization falling below 500 million yuan for 20 consecutive trading days [5][6] Group 3: Performance Forecasts - Foton Motor expects a net profit increase of approximately 1551% to around 1.33 billion yuan in 2025, driven by sales growth across various segments [7] - Beimo High-Tech anticipates a net profit of 190 million to 220 million yuan, reflecting a growth of 1076.16% to 1261.87% [8] - Zhongke Sanhuan forecasts a net profit increase of 566.23% to 899.35%, driven by cost control and market expansion [9] - Wancheng Group expects a net profit of 1.23 billion to 1.4 billion yuan, a growth of 222.38% to 266.94% [10] - Wan Yi Technology anticipates a net profit increase of 191.52% to 330.34%, supported by product optimization and cost reduction measures [11] - Nanmo Biology expects a net profit of 24 million to 34 million yuan, a growth of 269.49% to 423.44% [12] - Bai'ao Saitou forecasts a net profit increase of 384.26% to 443.88%, benefiting from overseas market expansion [13] - Hailanxin anticipates a net profit of 40 million to 60 million yuan, a growth of 387.47% to 631.2% [14] - Panzhihua Coal expects a net profit of 318 million to 380 million yuan, a growth of 205.3% to 264.83% [15] - Huaguang New Materials forecasts a net profit increase of 104.67% to 141.88% [16] - Putian Technology expects a net profit of 1.92 million to 2.88 million yuan, a growth of 71.55% to 157.33% [17] - Guoda Special Materials anticipates a net profit increase of 82.61% [18] - Tongkun Co. expects a net profit of 1.95 billion to 2.15 billion yuan, a growth of 62.24% to 78.88% [19] - Yiming Pharmaceutical forecasts a net profit increase of 61.12% to 122.08% [20] - Guosheng Securities expects a net profit of 210 million to 280 million yuan, a growth of 25.44% to 67.25% [21] - Shengyi Technology anticipates a net profit increase of 87% to 98% [22] Group 4: Loss Forecasts - Saifutian expects a loss of 30 million to 45 million yuan, significantly reducing previous losses [23] - Magang Group forecasts a loss of 190 million to 250 million yuan, a substantial reduction in losses [24] - Shennong Seed Industry anticipates a profit of 90 million to 120 million yuan, reversing previous losses [25] - Jifeng Co. expects a profit of 410 million to 495 million yuan, reversing previous losses [26] - Bingchuan Network forecasts a profit of 436 million to 516 million yuan, reversing previous losses [27] - Zhongyou Technology anticipates a profit of 540 million to 640 million yuan, reversing previous losses [28] - Dongfang Biology expects a loss of 523 million yuan [29] - Wantai Biological anticipates a loss of 330 million to 410 million yuan due to market pressures [30] - Anbotong expects a loss of 114 million to 165 million yuan [31] - Shunxin Agriculture forecasts a loss of 116 million to 188 million yuan due to declining sales [32] - Guozhong Water expects a loss of 130 million to 104 million yuan, with potential delisting risks [33] Group 5: Major Contracts - China Communication Signal expects to win 21 major projects worth approximately 5.26 billion yuan [34]

Core Viewpoint - Yiming Pharmaceutical (002826.SZ) expects a net profit attributable to shareholders of 74 million to 102 million yuan for 2025, representing a year-on-year growth of 61.12% to 122.08% [1] - The net profit after deducting non-recurring gains and losses is projected to be between 39 million and 54 million yuan, indicating a year-on-year increase of 111.42% to 192.74% [1] Group 1 - The company is focusing on developing its own products in line with industry trends and policy directions [1] - Significant resources are being allocated to enhance the value and market share of self-produced products [1] - The sales growth of the core proprietary product, Miglitol tablets, has contributed to the overall profit increase, laying a foundation for the company's long-term stable development [1]